Introduction
death, breast cancer, TNBC, Talazoparib, Cancer
CANCER, RECURRENCE, BREAST CANCER
Despite the overall progress in breast cancer treatments, some patients continue to have a high risk of recurrence and death after systemic therapy.Cancer cells with germline Neoadjuvant chemotherapy has become a standard approach for most patients with early-stage TNBC,In the phase III BrighTNess study, the PARP inhibitor veliparib plus carboplatin in addition to weekly neoadjuvant paclitaxel followed by doxorubicin and cyclophosphamide in patients with TNBC demonstrated a clinically significant improvement of pathologic complete response (pCR) vs. paclitaxel alone followed by doxorubicin and cyclophosphamide (Talazoparib is a PARP inhibitor approved in the United States, the European Union, and multiple other countries as monotherapy for the treatment of patients with deleterious or suspected deleterious germline 